|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7020 EUR | +8.33% |
|
+26.03% | -54.30% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 1.38M | - | 54.43% | - | - | - | |
| 65.01B | 28.08% | 41.19% | 45.52% | 17.73% | 1.07x | |
| 24.78B | 12.36% | 17.06% | 12.4% | 5.06% | 1.51x | |
| 1.4B | 22.69% | 33.58% | 153.59% | - | 3.59x | |
| 3.17B | 13.49% | 20.59% | 7.7% | 8.02% | -1.69x | |
| 490M | 37.77% | 28.86% | 39.28% | 22.66% | -1.18x | |
| 1.51B | 8.48% | 4.77% | 8.21% | 6.3% | -0.32x | |
| 516M | 8.46% | 11.59% | 5.02% | - | 2.04x | |
| 719M | -5.36% | 22.07% | 12.89% | - | - | |
| 79.95M | -5.75% | -1.06% | - | - | - | |
| 613M | 14.15% | -3% | 6.3% | -0.45% | -30.97x | |
| 84.61M | -45.97% | -61.26% | -6.62% | -5.3% | - | |
| 69.16M | 54.84% | 52.17% | 34.27% | 26.13% | -1.72x | |
| Average | 7.57B | 11.94% | 17% | 28.96% | 10.02% | -3.08x | |
| Weighted average by Cap. | 52.62B | 24.29% | 35.22% | 40.41% | 15.13% | 1.04x |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
